dNerva® TLD ke mokhoa oa bronchoscopic o sitisang ho kenngoa ha methapo ea matšoafo matšoafong ho fokotsa liphello tsa kliniki tsa ts'ebetso ea methapo ea kutlo. Ka mokhoa o ts'oanang le anticholinergics (sehlopha se ka sehloohong sa lithethefatsi tsa COPD) tse nooang letsatsi le letsatsi ho laola matšoao, ts'ebetso ea nako e le 'ngoe ea dNerva e na le monyetla oa ho fokotsa kotsi ea ho mpefala, ho ntlafatsa matšoao, le ho tsitsisa tšebetso ea matšoafo.
Kalafo ea bo-300 ea dNerva TLD e etsahetse khoeling ena. Dr. Gerard Criner, Molula-setulo le Moprofesa, Meriana ea Thoracic le Opereishene Sekolong sa Bongaka sa Lewis Katz Univesithing ea Temple e tšoere bakuli ba 20 tekong ea AIRFLOW-3. "Haeba re ka thusa bakuli ho tsitsisa matšoao a bona a COPD le ho ba thibela ho tsoa sepetlele, seo se tla thusa bakuli, bahlokomeli ba bona, le ho fokotsa moroalo tsamaisong ea tlhokomelo ea bophelo bo botle," o ile a re. Ho mpefala ha COPD ho emela hoo e ka bang karolo ea bobeli ho tse tharo ea kakaretso ea litšenyehelo tsa tlhokomelo ea COPD, e hakanyetsoang ho $49B selemo le selemo US.
Khoeli ena hape e tšoaea mohato oa bohlokoa oa kalafo tekong ea AIRFLOW-3. Prof. Pallav Shah, Ngaka ea Setsebi Sepetleleng sa Chelsea & Westminster le Royal Brompton London le Moprofesa oa Meriana ea ho Phefumoloha Imperial College ke eena ea ingolisang ea ka sehloohong tekong. O ile a etsa ts'ebetso ea 200th AIRFLOW-3 ho mokuli ea nang le COPD e itekanetseng ho isa ho e boima, moroalo o matla oa matšoao, le histori ea ho mpefala ha COPD ho sa tsotellehe tsamaiso e nepahetseng ea bongaka. O ile a re: "Bakuli ba bangata ba COPD ba na le bophelo bo bobe ka lebaka la ho eketseha ha COPD khafetsa." "Teko ea AIRFLOW-3 ke monyetla o monate oa ho lekola ts'ebetso ea nako e le 'ngoe ea bakuli ba kantle ho naha e ka fokotsang ho ata ha COPD le ho ntlafatsa botsitso ba bongaka."
Khampani e sa tsoa fumana boitlamo bo eketsehileng ba liranta tse limilione tse 50 tsa likoloto le lichelete tsa lichelete le Innovatus Capital Partners, LLC, tse tla sebelisoa ho phethela teko ea AIRFLOW-3 le ho fumana tumello ea US FDA.
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- He performed the 200th AIRFLOW-3 procedure in a patient with moderate-to-severe COPD, high symptom burden, and a history of COPD exacerbations despite optimal medical management.
- Gerard Criner, Chair and Professor, Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University has treated 20 patients in the AIRFLOW-3 trial.
- Mechanistically similar to anticholinergics (the principal class of COPD drugs) taken daily to manage symptoms, the one-time dNerva procedure has the potential to reduce exacerbation risk, improve symptoms, and stabilize lung function.
